<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Times,Italic" color="#000000"/>
	<fontspec id="font2" size="12" family="Helvetica,Bold" color="#ffffff"/>
	<fontspec id="font3" size="10" family="Times,Italic" color="#000000"/>
	<fontspec id="font4" size="7" family="Times,Italic" color="#000000"/>
	<fontspec id="font5" size="6" family="Times,Italic" color="#000000"/>
	<fontspec id="font6" size="10" family="Times" color="#000000"/>
	<fontspec id="font7" size="7" family="Times" color="#000000"/>
	<fontspec id="font8" size="11" family="Times,Bold" color="#000000"/>
<text top="42" left="279" width="54" height="8" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">FRASER et al.<i>et al.</i></text>
<text top="754" left="534" width="20" height="11" font="font2" id="p1_t2" reading_order_no="114" segment_no="2" tag_type="text">107<b>107</b></text>
<text top="765" left="227" width="161" height="9" font="font3" id="p1_t3" reading_order_no="113" segment_no="22" tag_type="text">C URRENT O NCOLOGY — V OLUME 14, N UMBER 3<i>C</i></text>
<text top="84" left="55" width="239" height="9" font="font6" id="p1_t4" reading_order_no="1" segment_no="1" tag_type="text">tario, Canada, for review and feedback in accordance<i>URRENT</i></text>
<text top="93" left="55" width="239" height="11" font="font6" id="p1_t5" reading_order_no="2" segment_no="1" tag_type="text">with the practice guidelines development cycle 32,33 .<i> O</i></text>
<text top="116" left="55" width="57" height="9" font="font8" id="p1_t6" reading_order_no="3" segment_no="4" tag_type="title">6.1 Methods<i>NCOLOGY</i></text>
<text top="138" left="55" width="239" height="9" font="font6" id="p1_t7" reading_order_no="4" segment_no="5" tag_type="text">A sample of 95 hematologists in Ontario received<i>—</i></text>
<text top="150" left="55" width="239" height="9" font="font6" id="p1_t8" reading_order_no="5" segment_no="5" tag_type="text">the survey, which consisted of items evaluating the<i>V</i></text>
<text top="161" left="55" width="239" height="9" font="font6" id="p1_t9" reading_order_no="6" segment_no="5" tag_type="text">methods, results, and interpretive summary used to<i>OLUME</i></text>
<text top="171" left="55" width="239" height="9" font="font6" id="p1_t10" reading_order_no="7" segment_no="5" tag_type="text">inform the draft recommendations and asking whether<i> 14, N</i></text>
<text top="183" left="55" width="239" height="9" font="font6" id="p1_t11" reading_order_no="8" segment_no="5" tag_type="text">the draft recommendations should be approved as a<i>UMBER</i></text>
<text top="194" left="55" width="239" height="9" font="font6" id="p1_t12" reading_order_no="9" segment_no="5" tag_type="text">practice guideline. Written comments were invited.<i> 3</i></text>
<text top="204" left="55" width="239" height="9" font="font6" id="p1_t13" reading_order_no="10" segment_no="5" tag_type="text">The practitioner feedback survey was mailed</text>
<text top="216" left="55" width="239" height="9" font="font6" id="p1_t14" reading_order_no="11" segment_no="5" tag_type="text">April 13, 2006, and a complete repeat mailing was</text>
<text top="227" left="55" width="239" height="9" font="font6" id="p1_t15" reading_order_no="12" segment_no="5" tag_type="text">sent thereafter. The Hematology DSG reviewed the</text>
<text top="237" left="55" width="95" height="9" font="font6" id="p1_t16" reading_order_no="13" segment_no="5" tag_type="text">results of the survey.</text>
<text top="259" left="55" width="51" height="9" font="font8" id="p1_t17" reading_order_no="14" segment_no="10" tag_type="title">6.2 Results<b>6.1 Methods</b></text>
<text top="282" left="55" width="239" height="9" font="font6" id="p1_t18" reading_order_no="15" segment_no="11" tag_type="text">A total of 63 responses were received from among</text>
<text top="293" left="55" width="239" height="9" font="font6" id="p1_t19" reading_order_no="16" segment_no="11" tag_type="text">the 95 questionnaires mailed, for a response rate of</text>
<text top="303" left="55" width="239" height="9" font="font6" id="p1_t20" reading_order_no="17" segment_no="11" tag_type="text">66%. Of the 63 respondents, 30 (48%) indicated that</text>
<text top="315" left="55" width="239" height="9" font="font6" id="p1_t21" reading_order_no="18" segment_no="11" tag_type="text">they cared for patients for whom the guideline is rel-</text>
<text top="326" left="55" width="174" height="9" font="font6" id="p1_t22" reading_order_no="19" segment_no="11" tag_type="text">evant, and they completed the survey.</text>
<text top="336" left="73" width="221" height="9" font="font6" id="p1_t23" reading_order_no="20" segment_no="12" tag_type="text">Overall, respondents showed strong support for</text>
<text top="348" left="55" width="239" height="9" font="font6" id="p1_t24" reading_order_no="21" segment_no="12" tag_type="text">the guideline. For questions that addressed issues such</text>
<text top="359" left="55" width="239" height="9" font="font6" id="p1_t25" reading_order_no="22" segment_no="12" tag_type="text">as the rationale for the guideline, the quality of the</text>
<text top="369" left="55" width="239" height="9" font="font6" id="p1_t26" reading_order_no="23" segment_no="12" tag_type="text">guideline, and the clarity of the recommendations, a</text>
<text top="381" left="55" width="239" height="9" font="font6" id="p1_t27" reading_order_no="24" segment_no="12" tag_type="text">substantial majority of respondents (87%–100%) ex-</text>
<text top="392" left="55" width="239" height="9" font="font6" id="p1_t28" reading_order_no="25" segment_no="12" tag_type="text">pressed modest to “strong” support for the report</text>
<text top="402" left="55" width="239" height="9" font="font6" id="p1_t29" reading_order_no="26" segment_no="12" tag_type="text">(1 or 2 on a scale of 1–5, with 1 being “strongly</text>
<text top="414" left="55" width="239" height="9" font="font6" id="p1_t30" reading_order_no="27" segment_no="12" tag_type="text">agree,” 3 being “neither agree or disagree,” and<b>6.2 Results</b></text>
<text top="425" left="55" width="133" height="9" font="font6" id="p1_t31" reading_order_no="28" segment_no="12" tag_type="text">5 being “strongly disagree”).</text>
<text top="435" left="73" width="221" height="9" font="font6" id="p1_t32" reading_order_no="29" segment_no="15" tag_type="text">With respect to the appropriateness of the rec-</text>
<text top="447" left="55" width="239" height="9" font="font6" id="p1_t33" reading_order_no="30" segment_no="15" tag_type="text">ommendations, a majority of respondents agreed with</text>
<text top="458" left="55" width="239" height="9" font="font6" id="p1_t34" reading_order_no="31" segment_no="15" tag_type="text">the draft recommendations as stated (70%) and with</text>
<text top="468" left="55" width="239" height="9" font="font6" id="p1_t35" reading_order_no="32" segment_no="15" tag_type="text">their appropriateness for the target population (73%).</text>
<text top="480" left="55" width="239" height="9" font="font6" id="p1_t36" reading_order_no="33" segment_no="15" tag_type="text">Some respondents (20%) felt that the recommenda-</text>
<text top="491" left="55" width="239" height="9" font="font6" id="p1_t37" reading_order_no="34" segment_no="15" tag_type="text">tions were excessively rigid and could not be applied</text>
<text top="501" left="55" width="100" height="9" font="font6" id="p1_t38" reading_order_no="35" segment_no="15" tag_type="text">to individual patients.</text>
<text top="513" left="73" width="221" height="9" font="font6" id="p1_t39" reading_order_no="36" segment_no="18" tag_type="text">Respondents varied in their views regarding the</text>
<text top="524" left="55" width="239" height="9" font="font6" id="p1_t40" reading_order_no="37" segment_no="18" tag_type="text">clinical utility of the recommendations. Approximately</text>
<text top="534" left="55" width="239" height="9" font="font6" id="p1_t41" reading_order_no="38" segment_no="18" tag_type="text">half responded ambivalently when asked if the rec-</text>
<text top="546" left="55" width="239" height="9" font="font6" id="p1_t42" reading_order_no="39" segment_no="18" tag_type="text">ommendations would produce more benefit than harm.</text>
<text top="557" left="55" width="239" height="9" font="font6" id="p1_t43" reading_order_no="40" segment_no="18" tag_type="text">Responses on whether the recommendations provided</text>
<text top="567" left="55" width="239" height="9" font="font6" id="p1_t44" reading_order_no="41" segment_no="18" tag_type="text">options that would be acceptable to patients varied</text>
<text top="579" left="55" width="239" height="9" font="font6" id="p1_t45" reading_order_no="42" segment_no="18" tag_type="text">widely (31% agreed, 38% were ambivalent, and 31%</text>
<text top="590" left="55" width="239" height="9" font="font6" id="p1_t46" reading_order_no="43" segment_no="18" tag_type="text">disagreed). Most respondents (69%) replied</text>
<text top="600" left="55" width="239" height="9" font="font6" id="p1_t47" reading_order_no="44" segment_no="18" tag_type="text">ambivalently when asked if the effect of the recom-</text>
<text top="612" left="55" width="232" height="9" font="font6" id="p1_t48" reading_order_no="45" segment_no="18" tag_type="text">mendations on patient outcomes would be obvious.</text>
<text top="623" left="73" width="221" height="9" font="font6" id="p1_t49" reading_order_no="46" segment_no="20" tag_type="text">When asked to compare these recommendations</text>
<text top="633" left="55" width="239" height="9" font="font6" id="p1_t50" reading_order_no="47" segment_no="20" tag_type="text">with current practice, approximately half of the re-</text>
<text top="645" left="55" width="239" height="9" font="font6" id="p1_t51" reading_order_no="48" segment_no="20" tag_type="text">spondents felt that the questions were not applicable.</text>
<text top="656" left="55" width="239" height="9" font="font6" id="p1_t52" reading_order_no="49" segment_no="20" tag_type="text">More than half of the respondents (57%) would be</text>
<text top="666" left="55" width="239" height="9" font="font6" id="p1_t53" reading_order_no="50" segment_no="20" tag_type="text">comfortable with their patients receiving the care rec-</text>
<text top="678" left="55" width="239" height="9" font="font6" id="p1_t54" reading_order_no="51" segment_no="20" tag_type="text">ommended in the draft document, and a sizable ma-</text>
<text top="689" left="55" width="239" height="9" font="font6" id="p1_t55" reading_order_no="52" segment_no="20" tag_type="text">jority (70%) felt that the draft report should be</text>
<text top="699" left="55" width="151" height="9" font="font6" id="p1_t56" reading_order_no="53" segment_no="20" tag_type="text">approved as a practice guideline.</text>
<text top="711" left="73" width="221" height="9" font="font6" id="p1_t57" reading_order_no="54" segment_no="21" tag_type="text">Most respondents felt that implementing the</text>
<text top="722" left="55" width="239" height="9" font="font6" id="p1_t58" reading_order_no="55" segment_no="21" tag_type="text">recommendations would require no reorganization of</text>
<text top="84" left="318" width="239" height="9" font="font6" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">their practice, nor would it be technically challeng-</text>
<text top="95" left="318" width="239" height="9" font="font6" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">ing or expensive (57%–67%). About half of the re-</text>
<text top="105" left="318" width="239" height="9" font="font6" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">spondents felt that the recommendations would be</text>
<text top="117" left="318" width="239" height="9" font="font6" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">supported by a majority of their colleagues (52%),</text>
<text top="128" left="318" width="239" height="9" font="font6" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">but many responded ambivalently to that question</text>
<text top="138" left="318" width="32" height="9" font="font6" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">(34%).</text>
<text top="150" left="336" width="221" height="9" font="font6" id="p1_t65" reading_order_no="62" segment_no="6" tag_type="text">A strong majority of respondents (79%) indicated</text>
<text top="161" left="318" width="239" height="9" font="font6" id="p1_t66" reading_order_no="63" segment_no="6" tag_type="text">that they would use the guideline in their own prac-</text>
<text top="171" left="318" width="215" height="9" font="font6" id="p1_t67" reading_order_no="64" segment_no="6" tag_type="text">tice and would apply it to their patients (83%).</text>
<text top="193" left="318" width="164" height="9" font="font8" id="p1_t68" reading_order_no="65" segment_no="7" tag_type="title">6.3 Summary of Written Comments</text>
<text top="216" left="318" width="239" height="9" font="font6" id="p1_t69" reading_order_no="66" segment_no="8" tag_type="text">The main points contained in the written comments</text>
<text top="227" left="318" width="52" height="9" font="font6" id="p1_t70" reading_order_no="67" segment_no="8" tag_type="text">were these:</text>
<text top="249" left="318" width="4" height="9" font="font6" id="p1_t71" reading_order_no="68" segment_no="9" tag_type="list">•</text>
<text top="249" left="336" width="221" height="9" font="font6" id="p1_t72" reading_order_no="69" segment_no="9" tag_type="list">Two respondents felt that the drug should be made</text>
<text top="260" left="336" width="221" height="9" font="font6" id="p1_t73" reading_order_no="70" segment_no="9" tag_type="list">available to select patients. One respondent felt</text>
<text top="270" left="336" width="221" height="9" font="font6" id="p1_t74" reading_order_no="71" segment_no="9" tag_type="list">that alemtuzumab should be recommended for</text>
<text top="282" left="336" width="221" height="9" font="font6" id="p1_t75" reading_order_no="72" segment_no="9" tag_type="list">use in patients with CLL who are resistant to</text>
<text top="293" left="336" width="221" height="9" font="font6" id="p1_t76" reading_order_no="73" segment_no="9" tag_type="list">fludarabine-containing combination regiments</text>
<text top="303" left="336" width="221" height="9" font="font6" id="p1_t77" reading_order_no="74" segment_no="9" tag_type="list">with marrow infiltration as a primary treatment</text>
<text top="315" left="336" width="221" height="9" font="font6" id="p1_t78" reading_order_no="75" segment_no="9" tag_type="list">indication. This respondent noted that a response</text>
<text top="326" left="336" width="221" height="9" font="font6" id="p1_t79" reading_order_no="76" segment_no="9" tag_type="list">rate of 38% was observed in that subpopulation</text>
<text top="336" left="336" width="221" height="9" font="font6" id="p1_t80" reading_order_no="77" segment_no="9" tag_type="list">in a phase II trial, and that treatment options for</text>
<text top="348" left="336" width="164" height="9" font="font6" id="p1_t81" reading_order_no="78" segment_no="9" tag_type="list">such patients are extremely limited.<b>6.3 Summary of Written Comments</b></text>
<text top="359" left="318" width="4" height="9" font="font6" id="p1_t82" reading_order_no="79" segment_no="13" tag_type="list">•</text>
<text top="359" left="336" width="221" height="9" font="font6" id="p1_t83" reading_order_no="80" segment_no="13" tag_type="list">Two respondents commented that the wording</text>
<text top="369" left="336" width="221" height="9" font="font6" id="p1_t84" reading_order_no="81" segment_no="13" tag_type="list">of the recommendation was unusual. One sug-</text>
<text top="381" left="336" width="221" height="9" font="font6" id="p1_t85" reading_order_no="82" segment_no="13" tag_type="list">gested that specific criteria be given for the</text>
<text top="392" left="336" width="221" height="9" font="font6" id="p1_t86" reading_order_no="83" segment_no="13" tag_type="list">highly specific circumstances mentioned in the</text>
<text top="402" left="336" width="81" height="9" font="font6" id="p1_t87" reading_order_no="84" segment_no="13" tag_type="list">recommendation.</text>
<text top="414" left="318" width="4" height="9" font="font6" id="p1_t88" reading_order_no="85" segment_no="14" tag_type="list">•</text>
<text top="414" left="336" width="221" height="9" font="font6" id="p1_t89" reading_order_no="86" segment_no="14" tag_type="list">Two respondents agreed that the current recom-</text>
<text top="425" left="336" width="221" height="9" font="font6" id="p1_t90" reading_order_no="87" segment_no="14" tag_type="list">mendation was appropriate and that alemtuzumab</text>
<text top="435" left="336" width="215" height="9" font="font6" id="p1_t91" reading_order_no="88" segment_no="14" tag_type="list">should be used only in a clinical trial situation.</text>
<text top="457" left="318" width="117" height="9" font="font8" id="p1_t92" reading_order_no="89" segment_no="16" tag_type="title">6.4 Modifications/Actions</text>
<text top="480" left="318" width="239" height="9" font="font6" id="p1_t93" reading_order_no="90" segment_no="17" tag_type="text">The Hematology DSG reviewed and discussed the</text>
<text top="491" left="318" width="239" height="9" font="font6" id="p1_t94" reading_order_no="91" segment_no="17" tag_type="text">comments resulting from the practitioner feedback</text>
<text top="501" left="318" width="239" height="9" font="font6" id="p1_t95" reading_order_no="92" segment_no="17" tag_type="text">survey and addressed the written feedback as follows:</text>
<text top="524" left="318" width="4" height="9" font="font6" id="p1_t96" reading_order_no="93" segment_no="19" tag_type="list">•</text>
<text top="524" left="336" width="221" height="9" font="font6" id="p1_t97" reading_order_no="94" segment_no="19" tag_type="list">In their deliberations, the members of the DSG were</text>
<text top="534" left="336" width="221" height="9" font="font6" id="p1_t98" reading_order_no="95" segment_no="19" tag_type="list">unanimous in the view that the data included in</text>
<text top="546" left="336" width="221" height="9" font="font6" id="p1_t99" reading_order_no="96" segment_no="19" tag_type="list">the evidence summary were generally of low</text>
<text top="557" left="336" width="221" height="9" font="font6" id="p1_t100" reading_order_no="97" segment_no="19" tag_type="list">methodologic quality and were characterized by</text>
<text top="567" left="336" width="221" height="9" font="font6" id="p1_t101" reading_order_no="98" segment_no="19" tag_type="list">a lack of prospective comparative trials, thereby</text>
<text top="579" left="336" width="221" height="9" font="font6" id="p1_t102" reading_order_no="99" segment_no="19" tag_type="list">precluding the development of a definitive rec-</text>
<text top="590" left="336" width="221" height="9" font="font6" id="p1_t103" reading_order_no="100" segment_no="19" tag_type="list">ommendation to use alemtuzumab in patients with</text>
<text top="600" left="336" width="220" height="9" font="font6" id="p1_t104" reading_order_no="101" segment_no="19" tag_type="list">CLL . However, the DSG acknowledged that there</text>
<text top="612" left="336" width="221" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="19" tag_type="list">may be instances in which patients and physi-</text>
<text top="623" left="336" width="221" height="9" font="font6" id="p1_t106" reading_order_no="103" segment_no="19" tag_type="list">cians who are well informed of the risks and un-</text>
<text top="633" left="336" width="221" height="9" font="font6" id="p1_t107" reading_order_no="104" segment_no="19" tag_type="list">certain net clinical benefit might prefer treatment</text>
<text top="645" left="336" width="221" height="9" font="font6" id="p1_t108" reading_order_no="105" segment_no="19" tag_type="list">with alemtuzumab. In addition, individual mem-</text>
<text top="656" left="336" width="221" height="9" font="font6" id="p1_t109" reading_order_no="106" segment_no="19" tag_type="list">bers of the DSG shared anecdotal experiences in-<b>6.4 Modifications/Actions</b></text>
<text top="666" left="336" width="221" height="9" font="font6" id="p1_t110" reading_order_no="107" segment_no="19" tag_type="list">volving carefully selected patients who derived</text>
<text top="678" left="336" width="221" height="9" font="font6" id="p1_t111" reading_order_no="108" segment_no="19" tag_type="list">benefit from treatment with alemtuzumab. The</text>
<text top="689" left="336" width="221" height="9" font="font6" id="p1_t112" reading_order_no="109" segment_no="19" tag_type="list">DSG is fully aware that anecdotal clinical experi-</text>
<text top="699" left="336" width="221" height="9" font="font6" id="p1_t113" reading_order_no="110" segment_no="19" tag_type="list">ence is not a basis for informing a guideline rec-</text>
<text top="711" left="336" width="221" height="9" font="font6" id="p1_t114" reading_order_no="111" segment_no="19" tag_type="list">ommendation, but the group acknowledged that</text>
<text top="722" left="336" width="221" height="9" font="font6" id="p1_t115" reading_order_no="112" segment_no="19" tag_type="list">such experience is consistent with available data</text>
</page>
</pdf2xml>
